Search research articles
Contact Us
Filters
Showing results (31-40 of 57) with videos related to
Page
of 6
Sort By:
Alimentary Pharmacology & Therapeutics
|
August 18, 2009
Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief
C W Howden, L M Larsen, M C Perez, et al.
British Journal of Haematology
|
November 1, 1992
Skin necrosis with a low molecular weight heparin
E Ojeda, M C Perez, R Mataix, et al.
Revista Espanola De Estomatologia
|
November 1, 1980
[Peripheral giant cell granuloma as a primary manifestation of hyperparathyroidism]
J S Lopez Arranz, M A Caravia, D Antuna de Alaiz, et al.
Neurology
|
January 1, 1981
Stable remissions in myasthenia gravis
M C Perez, W L Buot, C Mercado-Danguilan, et al.
Natural Product Research
|
August 22, 2014
Composition of fatty acids, triacylglycerols and polar compounds of different walnut varieties (Juglans regia L.) from Tunisia
I Bouabdallah, I Bouali, E Martinez-Force, et al.
Alimentary Pharmacology & Therapeutics
|
February 13, 2009
Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis
D C Metz, C W Howden, M C Perez, et al.
The American Journal of Physiology
|
September 1, 1991
Role of intrarenal angiotensin II in mediating renal response to volume expansion
J M Pinilla, M C Perez, I Hernandez, et al.
Electromyography and Clinical Neurophysiology
|
July 1, 1982
Diagnostic yield of single fiber electromyography and other electrophysiological techniques in myasthenia gravis. II. Jitter and motor unit fiber density studies. Clinical remission and thymectomy evaluation
A Cruz Martinez, M T Ferrer, M C Perez Conde, et al.
Alimentary Pharmacology & Therapeutics
|
December 2, 2010
The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease
A H Dabholkar, C Han, M M Paris, et al.
Diabetologia
|
September 1, 1987
Prevalence of islet cell antibodies, insulin antibodies and hyperglycaemia in 2291 schoolchildren
M Bergua, J Solé, G Marion, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 57) with videos related to
Sort By:
Page
of 6
Alimentary Pharmacology & Therapeutics
|
August 18, 2009
Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief
C W Howden, L M Larsen, M C Perez, et al.
British Journal of Haematology
|
November 1, 1992
Skin necrosis with a low molecular weight heparin
E Ojeda, M C Perez, R Mataix, et al.
Revista Espanola De Estomatologia
|
November 1, 1980
[Peripheral giant cell granuloma as a primary manifestation of hyperparathyroidism]
J S Lopez Arranz, M A Caravia, D Antuna de Alaiz, et al.
Neurology
|
January 1, 1981
Stable remissions in myasthenia gravis
M C Perez, W L Buot, C Mercado-Danguilan, et al.
Natural Product Research
|
August 22, 2014
Composition of fatty acids, triacylglycerols and polar compounds of different walnut varieties (Juglans regia L.) from Tunisia
I Bouabdallah, I Bouali, E Martinez-Force, et al.
Alimentary Pharmacology & Therapeutics
|
February 13, 2009
Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis
D C Metz, C W Howden, M C Perez, et al.
The American Journal of Physiology
|
September 1, 1991
Role of intrarenal angiotensin II in mediating renal response to volume expansion
J M Pinilla, M C Perez, I Hernandez, et al.
Electromyography and Clinical Neurophysiology
|
July 1, 1982
Diagnostic yield of single fiber electromyography and other electrophysiological techniques in myasthenia gravis. II. Jitter and motor unit fiber density studies. Clinical remission and thymectomy evaluation
A Cruz Martinez, M T Ferrer, M C Perez Conde, et al.
Alimentary Pharmacology & Therapeutics
|
December 2, 2010
The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease
A H Dabholkar, C Han, M M Paris, et al.
Diabetologia
|
September 1, 1987
Prevalence of islet cell antibodies, insulin antibodies and hyperglycaemia in 2291 schoolchildren
M Bergua, J Solé, G Marion, et al.
Page
of 6